No match scores
Peptide finder
Plate 11
Goal map
Find by outcome
36
Goal pages
1
Record
The short answer
Pick what you want to change. See every compound measured for it in people, most people first. Each one shows what the study found, and the failures are counted. 70 of 453 compounds here have no study in people of any kind.
- Compounds
- 453
- No study in people
- 70
How this ranks
No match scores
Other tools print a match percentage. Nobody measured those numbers. This page shows how many people each goal was measured in, and names the goals nobody has measured in a person.
A thin record in people is usually about who pays for trials. It is not a verdict on the compound.
What users report sits next to the trial count. It is never added into it.
What are you trying to change?
Pick as many as you like. The number on each one is how many people it has been measured in across the whole archive. So you can see where the evidence is before you choose.
Somebody handed you a stack. What is actually known about it?
Add what you are looking at. You get every goal those compounds have been measured for in people. Then you get the longer list of goals they have not.
Immune function
Does it help the immune system?
Vague as a goal and specific as a measurement. The trials here counted infections or counted cells; those are very different claims.
1,315 people · 8 studies in people · 6 compounds
- 01Thymalin with epitalonBlendStrong. At least two finished studies in people, and at least 1,000 people who took it. 2 completed trials, 1,106 people given it.7 reported1,106 people1 study1 found nothing
found nothingA defined thymus peptide was put through a modern study, and it failed. Just over a thousand people seriously ill with sepsis got either thymosin alpha-1 or a dummy shot, and nobody involved knew which. A month later, the same share had died in each group. It is on this page as a contrast. When a thymus peptide is...
BMJ, 2025 · 1,106 people
- 02ThymopentinPeptideModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 306 people given it.3 reported206 people2 studies1 found nothing
found nothingIt was tested properly for preventing infections after cancer surgery and it did not work. Two hundred and six patients were split by chance around the time of their operation. Infections happened slightly less often on thymopentin, and the gap was small enough that chance explains it. Infections were no less severe...
British Journal of Surgery, 1994 · 206 people
People kept more of a key immune cell, and that is all this shows. Adults with HIV who had no symptoms were given thymopentin or a dummy injection for about six months, and nobody involved knew which. Those on the drug held on to a higher share of CD4 cells, the cells HIV destroys. That is a blood marker, not how...
AIDS, 1992 · number of people not given
- 03LeptinBiologicModerate. At least one finished study in people, and at least 100 people who took it. 6 completed trials, 844 people given it.5 reported3 people1 study
Give leptin to the rare children who have none and it transforms them. Three children born unable to make leptin were injected daily for up to four years. Appetite fell, fat mass fell, insulin and blood fats came back towards normal, and puberty arrived at the right age. Immune cells that had been depleted recovered...
Journal of Clinical Investigation, 2002 · 3 people
- 04Dimethyl fumarateSmall moleculeLimited. People have taken it in a published study, but fewer than 100 of them. 3 completed trials, 54 people given it.4 reportednumber of people not given2 studies
In relapsing multiple sclerosis, dimethyl fumarate roughly halved the relapse rate over two years compared with a dummy pill, and slowed disability. 27% and 26% on the two doses had a relapse, against 46% on the dummy pill. This is the trial behind the approval. Flushing, gut problems and lower lymphocyte counts were...
The New England Journal of Medicine, 2012 · number of people not given
The second approval trial, with an injected drug, glatiramer, as well as a dummy pill for comparison. Dimethyl fumarate cut relapses compared with the dummy pill, and so did glatiramer. Neither clearly slowed disability. It was not built to say which drug is better.
The New England Journal of Medicine, 2012 · number of people not given
- 05ThymalinPeptideModerate. At least one finished study in people, and at least 100 people who took it. 4 completed trials, 308 people given it.7 reportednumber of people not given1 study
A small Russian trial about timing the dose, not about whether the drug works. Women of reproductive age with long-running inflammation of the tubes and ovaries were given thymalin, timed to their own immune cells' activity. Improvement in symptoms, blood tests and immune measures was more common when the drug was...
Bulletin of Experimental Biology and Medicine, 2015 · number of people not given
- 06EverolimusSmall moleculeStrong. At least two finished studies in people, and at least 1,000 people who took it. 3 completed trials, 1,024 people given it.number of people not given1 study
The follow up was larger and the result held. Older adults took a low dose combination of two mTOR blocking drugs for six weeks. They reported fewer infections over the following year and their immune response improved. This is the strongest positive result the programme produced. The large trial that came next did...
Science Translational Medicine, 2018 · number of people not given
- 07VilonPeptideAnimal or lab only. Only animal or lab studies on this page. No study in people yet. 1 animal study, 1 lab study, no human study.6 reportednumber of people not given0 studies
In a dish. In human and rat thymus cells, Vilon pushed young immune cells to mature.
Bulletin of Experimental Biology and Medicine, 2013 · number of people not given
- 08BronchogenPeptideAnimal or lab only. Only animal or lab studies on this page. No study in people yet. 2 lab studies, no human study.4 reportednumber of people not given0 studies
In a test tube. Bronchogen made DNA from calf and mouse cells a little harder to pull apart. That is a chemistry result, not a lung effect. Like the rest of this peptide's research, it comes from one research group. The paper lists the building blocks in a different order from the one sellers use.
Bulletin of Experimental Biology and Medicine, 2011 · number of people not given
- 09DT2216Small moleculeLimited. People have taken it in a published study, but fewer than 100 of them. 1 completed trial, 20 people given it.3 reportednumber of people not given0 studies
In mice and in a dish. DT2216 worked against a type of lymph cancer that needs BCL-xL. That adds to the lab case for destroying the protein instead of just blocking it.
Journal of Hematology and Oncology, 2020 · number of people not given
- 10ISRIBSmall moleculeAnimal or lab only. Only animal or lab studies on this page. No study in people yet. 3 animal studies, 1 lab study, no human study.4 reportednumber of people not given0 studies
In mice. This is the only ageing result. In old mice, ISRIB undid memory loss for places and improved short-term memory. In the memory part of the brain, nerve cells worked more like young ones and regrew contact points. Signs of immune activity in the brain went down. It measured memory, not lifespan. Several authors...
eLife, 2020 · number of people not given
- 11Senolytic vaccine (anti-GPNMB)BiologicAnimal or lab only. Only animal or lab studies on this page. No study in people yet. 3 animal studies, no human study.number of people not given0 studies
In mice. A different team built a tiny-particle vaccine against GPNMB. Given as a shot under the skin, it switched on killer immune cells that cleared zombie fat and heart cells in fast-ageing mice on a high-fat diet. Fat handling and heart function improved. A second team got a similar result, still in mice.
Human Vaccines and Immunotherapeutics, 2025 · number of people not given
- 12CerebrolysinPeptideStrong. At least two finished studies in people, and at least 1,000 people who took it. 3 completed trials, 1,591 people given it.8 reportednumber of people not given0 studies
- 13Thymosin Alpha-1PeptideStrong. At least two finished studies in people, and at least 1,000 people who took it. 2 completed trials, 1,204 people given it.7 reportednumber of people not given0 studies
- 14Thymosin alpha-1 with KPV and LL-37BlendStrong. At least two finished studies in people, and at least 1,000 people who took it. 3 completed trials, 1,140 people given it.6 reportednumber of people not given0 studies
How this is counted
Studies in people only. Animal and lab work never goes into this ranking, because your question was about a person.
A compound is listed for a goal only when a study on its own page names that goal and reports a result for it. Just naming it is not enough. Say a paper measures testosterone but reports a result about something else. That does not count as testosterone evidence. This tool made that mistake on its first run, and it no longer does.
People counts come from the study lines themselves, and when in doubt they count low. If a line gives no number, the study still counts as a study but adds nobody to the people count. Counts are never added up across compounds, because the same person can be in more than one trial.
The order is by how many people were measured. That is a fact about the evidence, not a judgement about the compound. It is the only order this site will defend. A compound at the top of a list is the most studied. That is not the same as the best.
Nothing here is advice. Nothing here tells you to take anything.